Financial Snapshot

Revenue
$839.1K
TTM
Gross Margin
76.36%
TTM
Net Earnings
-$526.4K
TTM
Current Assets
Q4 2024
Current Liabilities
Q4 2024
Current Ratio
1239.93%
Q4 2024
Total Assets
Q4 2024
Total Liabilities
Q4 2024
Book Value
$6.185M
Q4 2024
Cash
Q4 2024
P/E
-124.8
Nov 29, 2024 EST
Free Cash Flow

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2024 2023 2022 2021
Revenue $448.2K $628.6K $679.8K $702.8K
YoY Change -28.7% -7.53% -3.27%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2024 2023 2022 2021
Revenue $448.2K $628.6K $679.8K $702.8K
Cost Of Revenue $67.04K $157.8K $121.6K $112.0K
Gross Profit $381.2K $470.8K $558.2K $590.8K
Gross Profit Margin 85.04% 74.9% 82.11% 84.06%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2024 2023 2022 2021
Selling, General & Admin $1.058M $693.0K $456.9K $371.4K
YoY Change 52.68% 51.68% 23.01%
% of Gross Profit 277.6% 147.19% 81.86% 62.88%
Research & Development $93.32K $84.47K $73.72K $81.22K
YoY Change 10.48% 14.58% -9.23%
% of Gross Profit 24.48% 17.94% 13.21% 13.75%
Depreciation & Amortization $63.13K $54.08K $65.95K
YoY Change 16.73% -18.0%
% of Gross Profit 13.41% 9.69% 11.16%
Operating Expenses $1.151M $777.5K $530.6K $452.7K
YoY Change 48.09% 46.53% 17.22%
Operating Profit -$770.3K -$306.7K $27.52K $138.1K
YoY Change 151.16% -1214.39% -80.07%

Interest Expenses

No data

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2024 2023 2022 2021
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $131.5K $46.17K $43.51K $65.44K
YoY Change 184.83% 6.11% -33.51%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2024 2023 2022 2021
Pretax Income -$638.8K -$260.5K $71.03K $203.5K
YoY Change 145.2% -466.76% -65.1%
Income Tax $21.83K -$19.29K -$12.95K $11.07K
% Of Pretax Income -18.23% 5.44%
Net Earnings -$660.6K -$241.2K $83.98K $192.5K
YoY Change 173.85% -387.24% -56.36%
Net Earnings / Revenue -147.39% -38.37% 12.35% 27.39%
Basic Earnings Per Share -$0.05 -$0.02 $0.01
Diluted Earnings Per Share -$0.05 -$0.02 $0.01 $0.02

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

No data

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

No data

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

No data

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2024 2023 2022 2021
Cash & Short-Term Investments $217.9K $72.29K $136.8K
YoY Change 201.41% -47.14%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $27.87K $18.65K $13.01K
YoY Change 49.44% 43.35%
Inventory $52.26K $152.8K $99.43K
Prepaid Expenses
Receivables $206.3K $448.1K $209.5K
Other Receivables $28.13K $27.02K $557.3K
Total Short-Term Assets $532.5K $718.8K $1.016M
YoY Change -25.92% -29.25%
Property, Plant & Equipment $215.0K $217.9K $295.7K
YoY Change -1.34% -26.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $869.2K $465.0K $19.25K
YoY Change 86.91% 2315.58%
Total Long-Term Assets $1.084M $682.9K $315.0K
YoY Change 58.76% 116.83%
Total Assets $1.617M $1.402M $1.331M
YoY Change
Accounts Payable $18.00K $11.17K $24.43K
YoY Change 61.15% -54.28%
Accrued Expenses $88.64K $86.31K $85.94K
YoY Change 2.7% 0.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.205M $680.4K $135.8K
YoY Change 77.16% 401.14%
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $105.0K $165.0K $240.9K
YoY Change -36.37% -31.5%
Total Long-Term Liabilities $105.0K $165.0K $240.9K
YoY Change -36.37% -31.5%
Total Liabilities $1.310M $845.4K $376.7K
YoY Change 55.0% 124.46%

Ownership

Basic Shares Outstanding

No data

Diluted Shares Outstanding

No data

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2024 2023 2022 2021
Basic Shares Outstanding 12.72M shares 12.00M shares 12.00M shares
Diluted Shares Outstanding 12.72M shares 12.00M shares 12.00M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $65.692 Million

About Pheton Holdings Ltd

Pheton Holdings Ltd is a CN-based company operating in Health Care Technology industry. The company is headquartered in Beijing, Beijing and currently employs 11 full-time employees. The company went IPO on 2024-09-05. Pheton Holdings Ltd is a holding company principally engaged in the provision of healthcare solutions through its subsidiary Beijing Feitian Zhaoye Technology Co., Ltd. (Beijing Feitian). The Company’s main businesses include development and commercialization of brachytherapy treatment planning system (TPS) specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. TPS is generally a computer software used in different types of radiotherapy. The Company’s main product is FTTPS, a user-oriented TPS for treating a wide variety of malignant tumors. Beijing Feitian’s product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device and others.

Industry: Electromedical & Electrotherapeutic Apparatus Peers: